Skip to content
thestock.space

As of 6 Nov 2026, Divi's Laboratories trades at 93.6× trailing earnings, above the industry P/E of 28.7×, and the shares are close to their 52-week high. It earns ROCE of 19% and ROE of 16%, and sales and net profit grew 11% and 12% a year over 3 years. It has almost no debt, and its dividend yield is 0.3%. It is a large-cap company with a market cap of ₹2.7 lakh crore, ranked 2nd of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 49% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year
Open
₹10,130.00
Day high
₹10,320.50
Day low
₹10,040.50
Prev. close
₹10,140.50
Volume
8.9 L

Health check

1 good · 3 fair · 2 to check
  • ReturnsAhead

    +49.0% over a year, better than 6 of 7 peers.

  • Price tagPricier

    P/E 93.6 vs industry 28.7.

  • GrowthSteady

    Sales +11.0%, profit +12.1% a year over 3 years.

  • ProfitabilityAverage

    ROCE 19.0% vs peer median 14.9%.

  • Balance sheetFair

    Practically debt-free, Piotroski 5 of 9.

  • Red flags1 to check

    P/E of 93.6 against an industry P/E of 28.7.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Large cap

₹2.7L Cr, #2 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹11,230 Cr · profit ₹2,925 Cr
Market cap
₹2.7L Cr
Large cap
P/E
93.6
Industry 28.7
Price to book
16.35
Peers 4.99
Dividend yield
0.29%
ROE
16.2%
Peers 13.6%
ROCE
19.0%
Peers 14.9%
Debt to equity
0.00
Debt ₹7.00 Cr
EPS (TTM)
₹110.21
Face value ₹2
OPM (TTM)
34.9%
Net margin 26.0%
Sales growth
+27.8%
Latest quarter vs a year ago
Profit growth
+65.5%
Latest quarter vs a year ago
Price to sales
24.40
EV/EBITDA 68.3

Strengths and risks

Strengths

  • Practically debt-free.
  • Quarterly profit up 65.5% on a year ago.
  • Quarterly sales up 27.8% on a year ago.
  • Net margin of 26.0%.
  • Positive operating cash flow in each of the last 4 years.

Risks to check

  • P/E of 93.6 against an industry P/E of 28.7.

Derived automatically from reported figures. Not a recommendation.

About Divi's Laboratories

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as astaxanthin, beta-carotene, lycopene, canthaxanthin, apocarotenal, and vitamins used in the food,…

Headquarters
Hyderabad
Employees
11,565
Sector
Healthcare
ISIN
INE361B01024
Website
divislabs.com

Price range

52 weeks

₹5,647.50₹10,320.50

Today

₹10,040.50₹10,320.50
Avg volume (3M)
5.4 L
1-year return
plus 49.0%
From 52-week high
0.0%

Analyst consensus

28 analysts
HoldMean target ₹8,693.46 minus 15.8%

The mean target is below today’s price.

Target range, with today’s price

Low ₹6,500.00High ₹11,700.00

Next results expected around 7 Nov 2026

Consensus from Yahoo Finance. Not a recommendation.

Peers · Drug Manufacturers - Specialty & Generic

Compare with peersScreen the whole industry
Company
SUNPHARMASun Pharmaceutical Industries1,860.00plus 1.69%4,46,27640.74.9917.9%13.1%28.2%10.4%10.6%0.86%plus 8.2%
DIVISLABDivi's Laboratories10,320.50plus 1.78%2,73,97793.616.3519.0%16.2%34.9%11.0%12.1%0.29%plus 49.0%
TORNTPHARMTorrent Pharmaceuticals4,750.00plus 0.85%1,80,67580.29.839.1%15.7%33.7%13.3%20.2%0.80%plus 31.7%
LAURUSLABSLaurus Labs2,340.00minus 0.26%1,26,43394.420.8619.5%24.0%30.4%3.8%4.0%0.09%plus 138.6%
ZYDUSLIFEZydus Lifesciences1,197.90plus 0.41%1,19,49128.64.2919.0%14.7%26.2%16.5%37.0%0.08%plus 22.8%
DRREDDYDr. Reddy's Laboratories1,373.00plus 0.51%1,14,46240.92.9614.2%7.3%15.9%11.0%−1.7%0.58%plus 13.8%
CIPLACipla1,411.00plus 0.49%1,13,99339.43.2214.9%8.3%17.3%7.2%11.5%0.92%minus 6.6%
MANKINDMankind Pharma2,540.00plus 0.87%1,04,91346.85.9713.7%13.6%26.5%17.7%14.3%0.00%plus 6.3%
Median of 7 peers–0.51%1,19,49140.94.9914.9%13.6%26.5%11.0%11.5%0.58%13.8%

Quarterly results

Consolidated, ₹ crore
SalesSelect a row below to chart it
₹ CrMar 25Jun 25Dec 25Mar 26Jun 26
2,5852,4102,6042,8313,080
–––+9.5%+27.8%
1,6991,6811,7141,8971,825
8867298909341,255
34.3%30.2%34.2%33.0%40.7%
861198815564
13666
107112118120133
––−74––
8647337809631,180
23.4%25.6%25.3%22.0%23.6%
662545583751902
–––+13.4%+65.5%
24.9320.4921.9828.3133.95

Sep 25 not reported by the data source.

Profit & loss

Yearly, ₹ crore
Sales CAGR 3Y
+11.0%
Profit CAGR 3Y
+12.1%
EPS CAGR 3Y
+12.1%
ROE
16.2%
Net profitSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
7,6657,7969,32510,476
–+1.7%+19.6%+12.3%
5,2955,5866,3527,034
2,3702,2102,9733,442
30.9%28.3%31.9%32.9%
338333346502
–3223
343378402463
411−70
2,3692,1632,9163,388
23.0%26.0%24.9%24.2%
1,8241,6002,1912,568
–minus 12.3%+36.9%+17.2%
68.6960.2782.5396.75

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore
Total assetsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
53535353
12,71413,51814,91616,708
4347
1,6681,8961,9593,265
14,43915,47016,93220,033
4,9485,6326,6988,769
2318971,2602,247
77826569
4,1363,7013,5393,236
5,0475,1585,3705,712
14,43915,47016,93220,033

Cash flow

Yearly, ₹ crore
Cash from operationsSelect a row below to chart it
₹ CrMar 2023Mar 2024Mar 2025Mar 2026
2,4591,2611,6532,738
−2,707−269−804−2,219
−797−799−799−804
−1,04519350−285
−473−1,003−1,438−2,520
1,986258215218
−796−796−796−797

Shareholding pattern

Source: NSE filings
51.9%
promoters
  • Promoters51.88%
  • Public48.12%
  • As of 30 Sep 2026
QuarterSplitPromotersPublicPromoter change
30 Sep 202651.88%48.12%0.00
30 Jun 202651.88%48.12%0.00
31 Mar 202651.88%48.12%0.00
31 Dec 202551.88%48.12%minus 0.01
30 Sep 202551.89%48.11%–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you